{"id":"dll3","name":"DLL3","symbol":"DLL3","route":"/targets/dll3/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2909","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000090932","uniprot":"https://www.uniprot.org/uniprotkb/Q9NYJ7/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q9NYJ7","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4630888","open-targets":"https://platform.opentargets.org/target/ENSG00000090932","civic":"https://civicdb.org/genes/10683/summary","oncokb":"https://www.oncokb.org/gene/DLL3","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DLL3","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=DLL3","depmap":"https://depmap.org/portal/gene/DLL3?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000090932-DLL3","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/10683","omim":"https://www.omim.org/entry/602768"}],"products":[{"id":"dji136","name":"DJI136","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/dji136/"},{"id":"obrixtamig","name":"Obrixtamig","status":"phase-3","modality":"DLL3 x CD3 bispecific T-cell engager","route":"/drugs/obrixtamig/"},{"id":"peluntamig","name":"Peluntamig","status":"phase-2","modality":"bispecific antibody","route":"/drugs/peluntamig/"},{"id":"rovalpituzumab-tesirine","name":"Rovalpituzumab tesirine","status":"withdrawn","modality":"ADC","route":"/drugs/rovalpituzumab-tesirine/"},{"id":"tarlatamab","name":"Tarlatamab","status":"approved","modality":"Bispecific T-cell engager (DLL3×CD3)","route":"/drugs/tarlatamab/"},{"id":"zl-1310","name":"ZL-1310","status":"phase-3","modality":"ADC","route":"/drugs/zl-1310/"}],"trials":[{"id":"dellphi-305","name":"DeLLphi-305","nct":"NCT06211036","phase":"3","status":"positive"},{"id":"dellphi-304","name":"DeLLphi-304","nct":"NCT05740566","phase":"3","status":"positive"},{"id":"nct03061812","name":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","nct":"NCT03061812","phase":"3","status":"completed"},{"id":"nct03033511","name":"A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)","nct":"NCT03033511","phase":"3"},{"id":"nct07005128","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","nct":"NCT07005128","phase":"3","status":"active"},{"id":"dllevate","name":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","nct":"NCT07218146","phase":"3","status":"recruiting"},{"id":"nct07472517","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","nct":"NCT07472517","phase":"3","status":"recruiting"},{"id":"nct07544654","name":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","nct":"NCT07544654","phase":"3","status":"recruiting"},{"id":"nct07778316","name":"Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)","nct":"NCT07778316","phase":"3","status":"recruiting"},{"id":"nct06117774","name":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","nct":"NCT06117774","phase":"3","status":"active"},{"id":"nct07637513","name":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer","nct":"NCT07637513","phase":"3","status":"planned"},{"id":"nct06502977","name":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","nct":"NCT06502977","phase":"2","status":"active"},{"id":"nct05060016","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","nct":"NCT05060016","phase":"2","status":"active"},{"id":"nct02674568","name":"Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer","nct":"NCT02674568","phase":"2","status":"completed"},{"id":"nct06745323","name":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","nct":"NCT06745323","phase":"2","status":"active"},{"id":"nct07203053","name":"A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2","nct":"NCT07203053","phase":"2","status":"recruiting"},{"id":"nct05882058","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","nct":"NCT05882058","phase":"2","status":"recruiting"},{"id":"nct07016230","name":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","nct":"NCT07016230","phase":"2","status":"recruiting"},{"id":"nct07423585","name":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","nct":"NCT07423585","phase":"2","status":"recruiting"},{"id":"nct05652686","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","nct":"NCT05652686","phase":"1/2","status":"recruiting"},{"id":"nct06885281","name":"A Study of ZL-1310 in Participants With Selected Solid Tumors","nct":"NCT06885281","phase":"1/2","status":"recruiting"},{"id":"nct07564401","name":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy","nct":"NCT07564401","phase":"1/2","status":"recruiting"},{"id":"nct07744256","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","nct":"NCT07744256","phase":"1/2","status":"recruiting"},{"id":"nct07480213","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","nct":"NCT07480213","phase":"1/2","status":"recruiting"},{"id":"nct07707895","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","nct":"NCT07707895","phase":"1/2","status":"planned"},{"id":"nct06814496","name":"Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors","nct":"NCT06814496","phase":"1/2","status":"recruiting"}],"pathways":["cancer-stem-cells-plasticity","lineage-plasticity-neuroendocrine","notch","resistance-routes-map"],"companies":["abbvie","abdera-therapeutics","amgen","boehringer-ingelheim","harpoon-therapeutics","ideaya-biosciences","novartis","phanes-therapeutics","zai-lab"],"keyPapers":["paper-dellphi-301-nejm-2023","paper-gay-sclc-subtypes-inflamed-cancer-cell-2021","paper-baine-sclc-subtype-immunohistochemistry-jto-2020","paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","paper-george-sclc-genomic-profiles-nature-2015"],"hotspots":[],"openQuestions":[{"id":"dll3-io-combination","question":"Does adding tarlatamab to first-line chemo-immunotherapy in small-cell lung cancer improve survival, and can DLL3 expression or subtype select patients?","stage":"clinical","actor":"industry","source":{"label":"DeLLphi-301, NEJM 2023","url":"https://doi.org/10.1056/NEJMoa2307980"}}],"assays":[],"resistance":[{"class":"ar-pathway","mechanism":"Lineage plasticity to neuroendocrine prostate cancer","category":"lineage"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}